請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/53134完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 游佳欣(Jiashing Yu) | |
| dc.contributor.author | Hsin-Yi Mao | en |
| dc.contributor.author | 毛馨儀 | zh_TW |
| dc.date.accessioned | 2021-06-15T16:46:25Z | - |
| dc.date.available | 2020-08-10 | |
| dc.date.copyright | 2015-08-10 | |
| dc.date.issued | 2015 | |
| dc.date.submitted | 2015-08-10 | |
| dc.identifier.citation | 1. Mohler, E.R., peripheral arterial disease. original investigation, 2003.
2. NHLBI, Facts About Peripheral Arterial Disease. NHLBI produced publications, 2006. 3. Brownrigg, J.R., N.C. Schaper, and R.J. Hinchliffe, Diagnosis and assessment of peripheral arterial disease in the diabetic foot. Diabet Med, 2015. 32(6): p. 738-47. 4. DUANE R. HENNION, M., and KELLY A. SIANO, MD, Tripler Army Medical Center, Honolulu, Hawaii, Diagnosis and Treatment of Peripheral Arterial Disease. Am Fam Physician, 2013. 5. Lawall, H., P. Bramlage, and B. Amann, Treatment of peripheral arterial disease using stem and progenitor cell therapy. J Vasc Surg, 2011. 53(2): p. 445-53. 6. Higashi, Y., et al., Autologous bone-marrow mononuclear cell implantation improves endothelium-dependent vasodilation in patients with limb ischemia. Circulation, 2004. 109(10): p. 1215-8. 7. Matoba, S., et al., Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia. Am Heart J, 2008. 156(5): p. 1010-8. 8. Azarnoush, K., et al., Enhancement of the functional benefits of skeletal myoblast transplantation by means of coadministration of hypoxia-inducible factor 1alpha. J Thorac Cardiovasc Surg, 2005. 130(1): p. 173-9. 9. Vacanti, R.L.a.J.P., Tissue Engineering. SCIENCE, 1993. 10. 李宣書, 淺談組織工程. 物理雙月刊, 2001. 11. Martin Körbling, M.D., and Zeev Estrov, M.D., Adult Stem Cells for Tissue Repair Massachusetts Medical Society, 2003. 12. Stamm, C., et al., Autologous bone-marrow stem-cell transplantation for myocardial regeneration. The Lancet, 2003. 361(9351): p. 45-46. 13. Zuk, P.A., et al., Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell, 2002. 13(12): p. 4279-95. 14. Gimble, J.M., A.J. Katz, and B.A. Bunnell, Adipose-derived stem cells for regenerative medicine. Circ Res, 2007. 100(9): p. 1249-60. 15. Madonna, R., Y.J. Geng, and R. De Caterina, Adipose tissue-derived stem cells: characterization and potential for cardiovascular repair. Arterioscler Thromb Vasc Biol, 2009. 29(11): p. 1723-9. 16. Gimble, J.M., Adipose-Derived Stem Cells. Humana Press, 2011. 17. Donna D. Alderman, D., Advances in Regenerative Medicine : High-density Platelet-rich Plasma and Stem Cell Prolotherapy For Musculoskeletal Pain. Practical Pain Management. Practical Pain Management, 2011. 18. Davies, J.A., Extracellular Matrix. Nature Publishing Group, 2001. 19. Griffith, L.G. and M.A. Swartz, Capturing complex 3D tissue physiology in vitro. Nat Rev Mol Cell Biol, 2006. 7(3): p. 211-24. 20. Haskill*, R.L.J.a.S., Signal Transduction from the Extracellular Matrix. The Journal of Cell Biology, 1993. 21. Chan, B.P. and K.W. Leong, Scaffolding in tissue engineering: general approaches and tissue-specific considerations. Eur Spine J, 2008. 17 Suppl 4: p. 467-79. 22. Senger, D.R., TUMOR-CELLS SECRETE A VASCULAR-PERMEABILITY FACTOR THAT PROMOTES ACCUMULATION OF ASCITES-FLUID. SCIENCE, 1983. 23. SCOTT, C.D., IMMOBILIZED CELLS - A REVIEW OF RECENT LITERATURE. Enzyme Microb. Technology., 1987. 24. Kourkoutas, Y., et al., Immobilization technologies and support materials suitable in alcohol beverages production: a review. Food Microbiology, 2004. 21(4): p. 377-397. 25. Federica Rusmini, Z.Z., *,† and Jan Feijen*, Protein Immobilization Strategies for Protein Biochips. Biomacromolecules, 2007. 26. Ephraim Katchalski-Katzir a, D.M.K.b., ),1, Eupergitw C, a carrier for immobilization of enzymes of industrial potential. Journal of Molecular Catalysis B: Enzymatic, 2000. 27. Chaplin, M.F.a.C.B., ENZYME TECHNOLOGY. Enzyme Technology, 1990. 28. Hartmeier, W., Immobilized biocatalysts- from simple to complex systems. Trends in Biotechnology. 29. Olav Smidsr?d, G.S.k.-B.k., Alginate as immobilization matrix for cells. TIBTECH- MARCH, 1990. 30. Chang, T.M.S., Pharmaceutical and therapeutic applications of artificial cells including microencapsulation. European Journal of Pharmaceutics and Biopharmaceutics, 1998. 45(1): p. 3-8. 31. Gheorghe Fundueanu!, C.N., Adrian Carpov#, Jacques Desbrieres!,Marguerite Rinaudo!,*, Physico-chemical characterization of Ca-alginate microparticles produced with different methods. biomaterials, 1999. 32. Gregor T. Grant1, E.R.M., David A. Rees, Peter J.C. Smith1, David Thom1, BIOLOGICAL INTERACTIONS BETWEEN POLYSACCHARIDES AND DIVALENT CATIONS - EGG-BOX MODEL. FEBS LETTERS 1973. 33. PETER S. J. CHEETHAM, K.W.B., and CHRISTOPHER BUCKE, Tare and Lyle Limited, Group Physical Studies on Cell Immobilization Using Calcium Alginate Gels Biotechnology and Bioengineering, 1979. 34. Bickerstaff, G.F., Immobilization of enzymes and cells: Some practical considerations. Methods in Biotechnology. 35. Wan, L.Q., et al., Calcium Concentration Effects on the Mechanical and Biochemical Properties of Chondrocyte-Alginate Constructs. Cell Mol Bioeng, 2008. 1(1): p. 93-102. 36. Smetana, K., CELL BIOLOGY OF HYDROGELS. Biomaterials, 1993. 37. L. ROHANI, K.K., A. VAHDATI, M. HATAMI, M.H. NASR-ESFAHANI, H. BAHARVAND, Embryonic stem cell sphere: a controlled method for production of mouse embryonic stem cell aggregates for differentiation. Tissue Engineering, 2008. 38. Yu, J., et al., The use of human mesenchymal stem cells encapsulated in RGD modified alginate microspheres in the repair of myocardial infarction in the rat. Biomaterials, 2010. 31(27): p. 7012-20. 39. Crapo, P.M., T.W. Gilbert, and S.F. Badylak, An overview of tissue and whole organ decellularization processes. Biomaterials, 2011. 32(12): p. 3233-43. 40. Flynn, L.E., The use of decellularized adipose tissue to provide an inductive microenvironment for the adipogenic differentiation of human adipose-derived stem cells. Biomaterials, 2010. 31(17): p. 4715-24. 41. Choi, J.S., et al., In vitro cartilage tissue engineering using adipose-derived extracellular matrix scaffolds seeded with adipose-derived stem cells. Tissue Eng Part A, 2012. 18(1-2): p. 80-92. 42. Choi, J.S., et al., Human extracellular matrix (ECM) powders for injectable cell delivery and adipose tissue engineering. J Control Release, 2009. 139(1): p. 2-7. 43. Rifkin, R.F.a.D.B., The Extracellular Regulation of Growth Factor Action. Molecular Biology of the Cell, 1992. 44. Calvin D Roskelley, A.S., Mina J Bissell,, A hierarchy of ECM-mediated signalling regulates tissue-specific gene expression. Current Opinion in Cell Biology, 1995. 45. R. DOCHERTY, J.V.F., J. M. LACKIE and D. W. GREGORY, Glycosaminoglycans facilitate the movement of fibroblasts through threedimensional collagen matrices. Journal of Cell Science, 1989. 46. Gilbert, T.W., T.L. Sellaro, and S.F. Badylak, Decellularization of tissues and organs. Biomaterials, 2006. 27(19): p. 3675-83. 47. Ji Suk Choi, M.S., Hyun-Jin Yang, M.D., Beob Soo Kim, B.S., Jae Dong Kim, B.S.,Sang Hoon Lee, Ph.D., Eun Kyu Lee, Ph.D., Kinam Park, Ph.D.,Yong Woo Cho, Ph.D. and Hee Young Lee, M.D., Ph.D., Fabrication of Porous Extracellular Matrix Scaffolds from Human Adipose Tissue. TISSUE ENGINEERING: Part C, 2010. 48. Choi, Y.C., et al., Decellularized extracellular matrix derived from porcine adipose tissue as a xenogeneic biomaterial for tissue engineering. Tissue Eng Part C Methods, 2012. 18(11): p. 866-76. 49. Young, D.A., et al., Injectable hydrogel scaffold from decellularized human lipoaspirate. Acta Biomater, 2011. 7(3): p. 1040-9. 50. Wu, I., et al., An injectable adipose matrix for soft-tissue reconstruction. Plast Reconstr Surg, 2012. 129(6): p. 1247-57. 51. Richard W. Farndale , D.J.B.a.A.J.B., Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochimica et Biophysica Acta, 1986. 52. ENWEMEKA, G.K.R.a.C.S., A Simplified Method for the Analysis ofin Biological Tissues Hydroxyproline. Clinical Biochemistry, 1996. 53. Karen J. Wiechelman, R.D.B., Jimmie D. Fitzpatrick, Investigation of the Bicinchoninic Acid Protein Assay: Identification of the Groups Responsible for Color Formation Analytical Biochemistry, 1988. 54. Krohn, R.I., The Colorimetric Detection and Quantitation of Total Protein. Current Protocols in Toxicology. Current Protocols in Toxicology, 2005. 55. Wang, H., et al., Ammonia-containing dimethyl sulfoxide: an improved solvent for the dissolution of formazan crystals in the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. Anal Biochem, 2012. 421(1): p. 324-6. 56. Ratner, B.D., The Engineering of Biomaterials Recognition and Specificity Exhibiting. JOURNAL. OF MOLECULAR RECOGNITION, 1996. 57. J Pickard, E.I., J Egan and J Fisher, Investigation into the effect of proteoglycan molecules on the tribological properties of cartilage joint tissues. Instn Mech Engrs, 1998. 58. Park, I.S., et al., The correlation between human adipose-derived stem cells differentiation and cell adhesion mechanism. Biomaterials, 2009. 30(36): p. 6835-43. 59. Moyer, H.R., et al., Alginate microencapsulation technology for the percutaneous delivery of adipose-derived stem cells. Ann Plast Surg, 2010. 65(5): p. 497-503. 60. Rosen, E.D. and O.A. MacDougald, Adipocyte differentiation from the inside out. Nat Rev Mol Cell Biol, 2006. 7(12): p. 885-96. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/53134 | - |
| dc.description.abstract | 周邊動脈疾病是一種不可忽視的疾病，近期治療方法使用對於組織的再生和血運重建，植入幹細胞療法是一個具有極大潛力的治療方式。幹細胞療法的目標是更換並修復或加強受損組織或器官的功能。脂肪幹細胞ASCs因具分化能力，有相較於其他幹細胞更為方便的萃取方法和充足的來源等優點，為一在組織工程和在生醫學領域上新興的幹細胞來源；然而，有兩個問題是在細胞移植或異種移植前需要解決的主要問題，如此一來才可以達到臨床應用所能接受的標準：控制免疫排斥反應以及控制植入的細胞其增殖的情形。
在本研究中，我們著重於去細胞的脂肪組織(DAT)，這是一種天然細胞外基質(ECM)。我們相信，從生物體本身提取的生物材料有很大的潛力作為支架材料的幹細胞培養，以及幫助組織重建，特別是天然的細胞外基質和幹細胞都是來自脂肪組織。我們將利用去細胞組織的溶液(DATsol)與海藻酸鈉的材料對於脂肪幹細胞ASCs的影響。 在這項實驗中，我們萃取DATsol並混合有高、低兩種分子量的海藻酸鈉培養脂肪幹細胞ASCs，進行了許多實驗研究。在二微的體外實驗研究表明，混有DATsol的海藻酸鈉可以成功促進脂肪幹細胞ASCs的貼附和分化；在混有DATsol的海藻酸鈉固定化脂肪幹細胞ASCs方面，顯示出混有DATsol之海藻酸鈉包覆細胞會使得細胞有較高的存活率，整體存活率都高於80％。我們認為使用脂肪幹細胞作為治療下肢缺血患者因病情嚴重而受到影響的病症發展，是個有潛力成為一種成熟且穩定的幹細胞治療方式。 | zh_TW |
| dc.description.abstract | Cell-based therapies, new and current regenerative treatment, can use stem cells to create living and functional tissues to regenerate and repair tissue and organs in the body. In peripheral arterial disease, it has been demonstrated that stem cell treatment can improve perfusion and stimulate neovascularization. However, it usually suffers from some deficiencies, like immune rejection and limited proliferation of implanted cells.
In this study, we focus on the application of the decellularize adipose tissue (DAT), which is a native extracellular matrix (ECM). We believe that the biomaterial extracted from the organism itself have great potential as a scaffold materials for stem cell culture as well as new tissue construct formation, especially the native ECM and stem cell are from the same origin (adipose tissue). We used DATsol (DAT solution) combined with alginate to culture Adipose stem cells (ASCs). In this work, we extracted DATsol to mix in high and low molecular weight alginate and investigated. The 2-D in virto study of DATsol/alginate could promote cell adhesion and differentiation; ASCs, immobilized in DATsol/alginate microspheres, showed metabolic activity which with an overall viability higher than 80%. We believe that the use of adult stem cell therapy in ischemia patients allows for the development of new mature and stable capillaries in patients affected by the severe condition. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-15T16:46:25Z (GMT). No. of bitstreams: 1 ntu-104-R02524077-1.pdf: 5597572 bytes, checksum: f28165b0e3657f804d84949177655147 (MD5) Previous issue date: 2015 | en |
| dc.description.tableofcontents | 誌謝.................................................................................................................................. 1
摘要.................................................................................................................................. 2 Abstract ............................................................................................................................. 3 圖目錄.............................................................................................................................. 7 表目錄.............................................................................................................................. 9 第一章 介紹.................................................................................................................. 10 1-1 組織工程......................................................................................................... 10 1-1-1 細胞.................................................................................................... 10 1-1-2 支架.................................................................................................... 12 1-1-3 訊息因子............................................................................................ 14 1-2 細胞固定化..................................................................................................... 14 1-3 海藻酸鈉......................................................................................................... 15 1-3-1 海藻酸鈉的凝膠性質........................................................................ 15 1-3-1 海藻酸鈉的表面性質........................................................................ 16 1-4 天然材料-去細胞脂肪組織........................................................................... 17 1-4-1 去細胞組織的成分及特性................................................................ 17 1-4-2 去細胞................................................................................................ 19 1-5 利用空氣動力機包埋細胞............................................................................ 22 1-6 周邊動脈疾病(peripheral artery disease)...................................................... 23 1-6-1 周邊動脈疾病治療方法.................................................................... 24 1-6-2 幹細胞治療周邊動脈疾病的潛能................................................... 25 第三章材料與方法 ...................................................................................................... 27 3-1 實驗設備........................................................................................................ 27 3-2 實驗藥品........................................................................................................ 29 5 3-3 實驗步驟........................................................................................................ 32 3-3-1 去細胞脂肪組織蛋白質溶液的萃取................................................ 32 3-3-2 去細胞的程度分析........................................................................... 34 3-3-3 豬的脂肪幹細胞培養與保存........................................................... 37 3-3-4 2-D 細胞培養於DATsol/海藻酸鈉的複合材料上..................... 40 3-3-5 脂肪幹細胞在DATsol/海藻酸鈉膜上的分化情形........................ 46 3-3-6 微囊固定化脂肪幹細胞.................................................................... 53 3-3-7 動物實驗........................................................................................... 56 第四章結果與討論 ...................................................................................................... 60 4-1 去細胞脂肪組織............................................................................................. 60 4-1-1 去細胞脂肪組織(DAT)..................................................................... 60 4-1-2 去細胞脂肪組織蛋白質溶液萃取(DATsol) .................................... 62 4-1-3 去細胞前後的GAGs 含量................................................................ 63 4-1-4 去細胞前後膠原蛋白含量................................................................ 64 4-2 豬的脂肪幹細胞培養..................................................................................... 65 4-3 二維細胞培養於DATsol/海藻酸鈉的複合材料........................................ 66 4-3-1 DATsol/海藻酸鈉的複合材料貼附測試.......................................... 66 4-3-2 DATsol/海藻酸鈉的複合材料增生測試.......................................... 69 4-3-3 ASCs 之脂肪細胞分化能力測定..................................................... 73 4-3-4 ASCs 之骨細胞分化能力測定......................................................... 75 4-3-5 ASCs 的體外基因表現量分析......................................................... 78 4-4 微囊固定化脂肪幹細胞................................................................................ 81 4-4-1 海藻酸鈉微囊球粒徑測試............................................................... 81 4-4-2 海藻酸鈉微囊球計細胞活性........................................................... 82 4-5 動物實驗........................................................................................................ 86 第五章 結論 .................................................................................................................. 90 參考文獻........................................................................................................................ 92 口試問答........................................................................................................................ 97 | |
| dc.language.iso | zh-TW | |
| dc.title | 製造去細胞脂肪組織/海藻酸鈉微球包覆豬的脂肪幹細胞於組織工程的應用 | zh_TW |
| dc.title | Fabrication of decellularized adipose tissue/alginate composite microspheres with pASCs encapsulation for tissue engineering | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 103-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 蔡偉博(Wei-Bor Tsai),陳賢燁(Hsien-Yeh Chen),劉澤英(Tse-Ying Liu) | |
| dc.subject.keyword | 脂肪幹細胞,去細胞的脂肪組織,海藻酸鈉,微載體,周邊動脈疾病, | zh_TW |
| dc.subject.keyword | Adipose derived stem cells (ASCs),Decellularize adipose tissue(DAT),Alginte,Microspheres,PAD, | en |
| dc.relation.page | 99 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2015-08-10 | |
| dc.contributor.author-college | 工學院 | zh_TW |
| dc.contributor.author-dept | 化學工程學研究所 | zh_TW |
| 顯示於系所單位： | 化學工程學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-104-1.pdf 目前未授權公開取用 | 5.47 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。